Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06VFF
|
|||
| Former ID |
DIB006423
|
|||
| Drug Name |
EGFR antisense DNA
|
|||
| Synonyms |
Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 1/2 | [1] | |
| Company |
University of Pittsburgh
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | EGFR messenger RNA (EGFR mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00903461) Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.